Seliciclib
Cat. No.：YN290477
CAS No. ：186692-46-6
| 产品名称: | Seliciclib |
| CAS No.: | 186692-46-6 |
| Chemical Name: | 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol |
| Synonyms: | Roscovitine; CYC202; R-roscovitine |
| 分子量: | 354.45 |
| 分子式: | C₁₉H₂₆N₆O |
| SMILES: | OC[C@H](NC1=NC(NCC2=CC=CC=C2)=C3C(N(C=N3)C(C)C)=N1)CC |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Seliciclib (Roscovitine) 是一种有效的，具有口服活性的，选择性的CDKs抑制剂，抑制CDK5，Cdc2和CDK2的IC50分别为0.2 μM，0.65 μM，0.7 μM。 |
| IC50和靶点: | [{name:"cdc2/cyclin B:0.65 μM (IC50)"},{name: "cdk2/cyclin A:0.7 μM (IC50)"},{name: "Cdk2/cyclin E2:0.7 μM (IC50)"},{name: "CDK5/p35:0.16 μM (IC50)"},{name: "GST-erk1:30 μM (IC50)"},{name: "erk1:34 μM (IC50)"},{name: "erk2:14 μM (IC50)"},{name: "IR tyrosine kinase:70 μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
McClue, S.J., Blake, D., Clarke, R., et al.In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)Int. J. Cancer102,463-468(2002)
Meijer, L., Borgne, A., Mulner, O., et al.Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5Eur. J. Biochem.243,527-536(1997)
Havlícek, L., Hanus, J., Vesely, J., et al.Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compoundsJ. Med. Chem.40,408-412(1997)
Bukanov, N.O., Smith, L.A., Klinger, K.W., et al.Long-lasting arrest of murine polycystic kiney disease with CDK inhibitor roscovitineNature444,949-952(2006)
